NanoVelos Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 9
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $1.12M
Latest Deal Amount
  • Investors
  • 6

NanoVelos General Information


Operator of a cancer research company intended to develop a method of coating active substances with nano-particles of polysaccharides. The company's technology transforms generics to super-generics via a dextran-based nano-particle delivery system and exhibits dramatically improved tumor targeting, enabling medical professionals in enhancing therapeutic efficacy while minimizing adverse effects on healthy tissues.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Primary Office
  • Rakowiecka 36
  • Room 260
  • Warsaw, 02-532
  • Poland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoVelos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 16-Dec-2017 $1.12M 00.000 00.000 Completed Generating Revenue
3. Early Stage VC 01-Jul-2015 Completed Generating Revenue
2. Grant $347K Completed Startup
1. Early Stage VC 10-Apr-2013 Completed Startup
To view NanoVelos’s complete valuation and funding history, request access »

NanoVelos Patents

NanoVelos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3761955-A1 Anthracycline encapsulated with polysaccharide for use in the treatment of tumours Pending 06-Mar-2018 0000000000
US-20210052616-A1 Anthracycline encapsulated with a polysaccharide for use in the treatment of tumours Pending 06-Mar-2018 00000000000

NanoVelos Executive Team (8)

Name Title Board Seat Contact Info
Izabela Gatazka Chief Financial Officer
Tomasz Ciach Ph.D Co-Founder & Board Member
Paweł Ciach Member of the Supervisory Board
Adam Kiciak Ph.D Chief Medical Officer
You’re viewing 4 of 8 executive team members. Get the full list »

NanoVelos Board Members (6)

Name Representing Role Since
Agata Stefanek Ph.D NanoVelos Board Member 000 0000
Marek Borzestowski Giza Polish Ventures President of the Supervisory Board 000 0000
Piotr Pietrzak Self Member of the Supervisory Board 000 0000
Tomasz Ciach Ph.D NanoVelos Co-Founder & Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

NanoVelos Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoVelos Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ZernikeMeta Ventures Venture Capital Minority 000 0000 000000 0
Michal Solowow Angel (individual) Minority 000 0000 000000 0
Giza Polish Ventures Venture Capital Minority 000 0000 000000 0
Krajowy Fundusz Kapitałowy Fund of Funds Minority 000 0000 000000 0
European Regional Development Fund (Brandenburg) Sovereign Wealth Fund 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »